site-logo
  • LiquidHALLMARK®
  • Resources
    • Publications
    • News & Events
  • Patients
  • Company
    • About Us
    • News & Events
    • Careers
    • Contact Us
  • Portal Login

News & Update: News

Lucence secures US Medicare approval for its cancer tests

Lucence secures US Medicare approval for its cancer tests

Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer

Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer

Lucence Shares Promising Interim Data from LIQUIK Prospective Study at ISLB 2022

Lucence Shares Promising Interim Data from LIQUIK Prospective Study at ISLB 2022

Lucence and Omnigen Partner to bring Amplicon-based Liquid Biopsy Tests to Turkey

Lucence and Omnigen Partner to bring Amplicon-based Liquid Biopsy Tests to Turkey

Lucence Collaborates with National Cancer Centre Singapore to Launch Prospective Liquid Biopsy Study for Prostate Cancer

Lucence Collaborates with National Cancer Centre Singapore to Launch Prospective Liquid Biopsy Study for Prostate Cancer

Local Study Demonstrates Synergies of Using Blood-based Liquid Biopsies to complement Tissue Biopsies for Lung Cancer Diagnosis

Local Study Demonstrates Synergies of Using Blood-based Liquid Biopsies to complement Tissue Biopsies for Lung Cancer Diagnosis

Lucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy

Lucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

Lucence Announces Publication of Validation Study for LiquidHALLMARK ctDNA Liquid Biopsy Assay

Lucence Announces Publication of Validation Study for LiquidHALLMARK ctDNA Liquid Biopsy Assay

Lucence’s LiquidHALLMARK Liquid Biopsy Assay Expands to Include cfRNA

Lucence’s LiquidHALLMARK Liquid Biopsy Assay Expands to Include cfRNA

Posts navigation

Older posts
Up arrow Back to top
Footer logo
Reach Us
3520 W Bayshore Road, Palo Alto, CA 94303 [email protected] (888) 582 3623
Subscribe for Updates

    Follow Us
    • facebook facebook-white
    • linkedin linkedin-white
    • twitter twitter-white

    © 2023 Lucence Health Inc. All rights reserved. All logos and trademarks are the property of Lucence or their respective owners.

    LiquidHALLMARK® | AmpliMark™ | Publications| Careers | About | Privacy

    Lucence secures approval for its Singapore-invented cancer tests from Medicare

    >